– Clovis seeks U.S. approval for rucaparib as monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer – FDA submission based on data from TRITON clinical program in advanced prostate cancer – FDA has assigned PDUFA date of…
Charles River and Takeda Enter Multi-Year Drug Discovery Deal
Takeda Pharmaceutical has been on a tear over the past few weeks, striking deals to develop new therapies for various diseases. On Monday, the Japan-based pharma powerhouse announced a multi-year drug discovery deal with Charles River Laboratories. Charles River will…
GSK’s CEO Walmsley aiming for six new approvals in 2020
GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in the next year. In an interview at the JP Morgan Healthcare Conference in San Francisco with CNBC, Walmsley said there is a…
AbbVie’s Skyrizi Beats Out Novartis’ Cosentyx in Plaque Psoriasis
AbbVie reported that its Skyrizi met both primary and all ranked secondary endpoints in its Phase III trial that went head-to-head with Novartis’ Cosentyx in plaque psoriasis. The Phase III, multicenter, randomized, open-label, efficacy assessor-blinded, active-comparator trial studied the safety…
Eli Lilly Bags Dermatology Company Dermira for $1.1 Billion
Not waiting for the start of the annual J.P. Morgan Healthcare Conference, Eli Lilly announced it will acquire California-based Dermira, Inc. in an all-cash deal for $1.1 billion. The acquisition will allow Eli Lilly to expand its immunology pipeline with a late-stage…
Blueprint gets first approval as FDA backs stomach cancer drug
US biotech Blueprint Medicines has its first approved drug, after the FDA backed its oncology drug Ayvakit for a certain kind of stomach cancer. The regulator approved Ayvakit (avapritinib) on the basis of high response rates seen in phase 1…
AI specialist Exscientia signs drug discovery tie-up with Bayer
UK artificial intelligence company Exscientia has added another big pharma company to its partner roster, with Bayer seeking to use its platform to find new cardiovascular and cancer drugs. Bayer is pledging up to €240 million ($266 million) in upfront…
Regeneron’s FOP Treatment Reduces New Lesions by 90%
Regeneron is eying potential regulatory approval of its treatment for a rare bone disease after Phase II clinical data showed an almost 90% reduction in the formation of new lesions in patients with fibrodysplasia ossificans progressiva (FOP). This morning, Regeneron…
Merck’s Keytruda Approved for High-Risk Bladder Cancer
Merck’s checkpoint inhibitor Keytruda (pembrolizumab) continues moving toward the projections of becoming the world’s best-selling drug. The company announced that the U.S. Food and Drug Administration (FDA) had approved the anti-PD-1 therapy as a monotherapy for patients with Bacillus Calmette-Guerin…
Biogen investment in Immuneel: Bringing CAR-T therapy to India
With nearly two million new cases and a million deaths each year in India, the war against cancer is amongst the most pressing crises in the country. Over the years, Eight Roads has had the privilege of partnering with companies…
